lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Exosomal LncRNA–NEAT1 Derived from MIF-Treated Mesenchymal Stem Cells Protected Against Doxorubicin-Induced Cardiac Senescence Through Sponging miR-221-3p

36 Pages Posted: 15 May 2020

See all articles by Lei Zhuang

Lei Zhuang

Department of Hepatobiliary Surgery, First Affiliated Hospital, Wenzhou Medical University

Wenzheng Xia

Shanghai Jiao Tong University (SJTU) - Department of Neurosurgery

Didi Chen

Department of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University

Shiting Li

Shanghai Jiao Tong University (SJTU) - Department of Neurosurgery

Meng Hou

Wenzhou Medical University - Department of Radiation and Medical Oncology

More...

Abstract

Background: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy ( DIC ). Previous studies reported that exosomes derived from mesenchymal stem cells (MSCs) pretreated with macrophage migration inhibitory factor (MIF) (exosomeMIF) showed a cardioprotective effect through modulating long noncoding RNAs/microRNAs (lncRNAs/miRs). This study aimed to investigate the role of exosome MIF in the treatment of DIC.

Method: Exosomes were isolated from control MSCs (exosome) and MIF-pretreated MSCs (exosomeMIF). Regulatory lncRNAs activated by MIF pretreatment were explored using genomics approaches. Fluorescence-labeled exosomes were tracked in vitro by fluorescence imaging. In vivo and in vitro, miR-221-3p mimic transfection enforced miR-221-3p overexpression, and senescence-associated β-galactosidase assay was applied to test cellular senescence. Exosomal delivering LncRNA-NEAT1 induced therapeutic effect in vivo was confirmed by echocardiography.

Finding: It demonstrated that exosomesMIF recovered the cardiac function and exerted the anti-senescent effect through LncRNA–NEAT1 transfer against Dox. TargetScan and luciferase assay showed that miR-221-3p targeted the Sirt2 3'-untranslated region. Silencing LncRNA–NEAT1 in MSCs, miR-221-3p overexpression or Sirt2 silencing in cardiomyocytes ruined the exosomeMIF -induced anti-senescent effect against Dox.

Interpretation: The results indicated exosomeMIF serving as a promising anti-senescent effector against Dox-induced cardiotoxicity through LncRNA–NEAT1 transfer, thus sponging miR-221-3p and leading to Sirt2 activation. The study proposed that exosomeMIF might have the potential to serve as a cardioprotective therapeutic agent during cancer chemotherapy.

Funding Statement: The present study was supported by the National Natural Science Foundation of China (grant nos. 81974186; 81671205 to STL), the Science and Technology Planning Project of Wenzhou (grant no. Y20190445 to LZ), and the Medical Science and Technology Project of Zhejiang Province (grant no. 2018KY517 to MH).

Declaration of Interests: Not applicable.

Ethics Approval Statement: All study procedures were approved by the Institutional Animal Care and Use Committee of Wenzhou Medical University. This study was conducted in compliance with the Guide for the Care and Use of Laboratory Animals published by the National Academy Press (NIH, revised in 1996).

Keywords: Mesenchymal stem cells; Exosome; Macrophage migration inhibitory factor (MIF); Doxorubicin-induced cardiomyopathy; LncRNA-NEAT1/miR-221-3p/Sirt2 signaling pathway

Suggested Citation

Zhuang, Lei and Xia, Wenzheng and Chen, Didi and Li, Shiting and Hou, Meng, Exosomal LncRNA–NEAT1 Derived from MIF-Treated Mesenchymal Stem Cells Protected Against Doxorubicin-Induced Cardiac Senescence Through Sponging miR-221-3p (3/18/2020). Available at SSRN: https://ssrn.com/abstract=3559518 or http://dx.doi.org/10.2139/ssrn.3559518

Lei Zhuang

Department of Hepatobiliary Surgery, First Affiliated Hospital, Wenzhou Medical University

Zhejiang Province
China

Wenzheng Xia

Shanghai Jiao Tong University (SJTU) - Department of Neurosurgery

Shanghai
China

Didi Chen

Department of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University

Zhejiang Province
China

Shiting Li

Shanghai Jiao Tong University (SJTU) - Department of Neurosurgery ( email )

Shanghai
China

Meng Hou (Contact Author)

Wenzhou Medical University - Department of Radiation and Medical Oncology ( email )

Wenzhou
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
70
Downloads
7